Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

por van der Veldt, A A M, Boven, E, van den Eertwegh, A J M, Haanen, J B A G
Publicado 2009

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

por van der Veldt, A A M, Meijerink, M R, van den Eertwegh, A J M, Haanen, J B A G, Boven, E
Publicado 2010

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

por Mulder, E.E.A.P., Smit, L., Grünhagen, D.J., Verhoef, C., Sleijfer, S., van der Veldt, A.A.M., Uyl-de Groot, C.A.
Publicado 2021

Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition

por de Joode, K., Oostvogels, A. A. M., GeurtsvanKessel, C. H., de Vries, R. D., Mathijssen, R. H. J., Debets, R., van der Veldt, A. A. M.
Publicado 2021

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective

por de Joode, K., Dumoulin, D.W., Engelen, V., Bloemendal, H.J., Verheij, M., van Laarhoven, H.W.M., Dingemans, I.H., Dingemans, A.C., van der Veldt, A.A.M.
Publicado 2020

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

por van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Publicado 2008

Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma

por Mulder, E.E.A.P., Dwarkasing, J.T., Tempel, D., van der Spek, A., Bosman, L., Verver, D., Mooyaart, A.L., van der Veldt, A.A.M., Verhoef, C., Nijsten, T.E.C., Grunhagen, D.J., Hollestein, L.M.
Publicado 2020

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma

por Derks, S.H.A.E., de Joode, K., Mulder, E.E.A.P., Ho, L.S., Joosse, A., de Jonge, M.J.A., Verhoef, C., Grünhagen, D.J., Smits, M., van den Bent, M.J., van der Veldt, A.A.M.
Publicado 2022

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies

por de Joode, K., van de Geer, W. S., van Leenders, G. J. L. H., Hamberg, P., Westgeest, H. M., Beeker, A., Oosting, S. F., van Rooijen, J. M., Beerepoot, L. V., Labots, M., Mathijssen, R. H. J., Lolkema, M. P., Cuppen, E., Sleijfer, S., van de Werken, H. J. G., van der Veldt, A. A. M.
Publicado 2023

LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors

por Oosting, S., Van der Veldt, A.A.M., GeurtsvanKessel, C.H., Fehrmann, R.S.N., van Binnendijk, R.S., Dingemans, A-M.C., Smit, E.F.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T., Battacharya, A., van der Heiden, M., Blank, C.U., Koopmans, M.P., van Els, C.A., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.
Publicado 2021

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

por Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., Uyl-de Groot, C.A.
Publicado 2021

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

por Oosting, S.F., van der Veldt, A.A.M., Fehrmann, R.S.N., Bhattacharya, A., van Binnendijk, R.S., GeurtsvanKessel, C.H., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T.T., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E.
Publicado 2023

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

por Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. Oomen-de, Franken, M. G., Ryll, B., Rutkowski, P., Sleijfer, S., Haanen, J. B. A. G., van der Veldt, A. A. M.
Publicado 2021

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

por van der Veldt, A.A.M., Oosting, S.F., Fehrmann, R.S.N., GeurtsvanKessel, C.H., van Binnendijk, R.S., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., Hartog, G. den, Jalving, M., Westphal, T.T., Bhattacharya, A., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E.
Publicado 2023